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Abstract
Background: The Cancer Stem Cell (CSC) hypothesis has gained credibility within the cancer research community.
According to this hypothesis, a small subpopulation of cells within cancerous tissues exhibits stem-cell-like characteristics
and is responsible for the maintenance and proliferation of cancer.
Methodologies/Principal Findings: We present a simple compartmental pseudo-chemical mathematical model for tumor
growth, based on the CSC hypothesis, and derived using a ‘‘chemical reaction’’ approach. We defined three cell
subpopulations: CSCs, transit progenitor cells, and differentiated cells. Each event related to cell division, differentiation, or
death is then modeled as a chemical reaction. The resulting set of ordinary differential equations was numerically integrated
to describe the time evolution of each cell subpopulation and the overall tumor growth. The parameter space was explored
to identify combinations of parameter values that produce biologically feasible and consistent scenarios.
Conclusions/Significance: Certain kinetic relationships apparently must be satisfied to sustain solid tumor growth and to
maintain an approximate constant fraction of CSCs in the tumor lower than 0.01 (as experimentally observed): (a) the rate of
symmetrical and asymmetrical CSC renewal must be in the same order of magnitude; (b) the intrinsic rate of renewal and
differentiation of progenitor cells must be half an order of magnitude higher than the corresponding intrinsic rates for
cancer stem cells; (c) the rates of apoptosis of the CSC, transit amplifying progenitor (P) cells, and terminally differentiated
(D) cells must be progressively higher by approximately one order of magnitude. Simulation results were consistent with
reports that have suggested that encouraging CSC differentiation could be an effective therapeutic strategy for fighting
cancer in addition to selective killing or inhibition of symmetric division of CSCs.
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Introduction
Fundamental and applied clinical research into cancer could
greatly benefit from mathematical models that contribute to the
basic understanding of this disease, to the planning of more
efficient therapeutic strategies, or to the generation of accurate
patient prognosis. This paper presents a general, simple, and
flexible mathematical model, mechanistically based on the Cancer
Stem Cell (CSC) hypothesis, that is capable of reproducing the
dynamics observed during the exponential growth of a tumor.
Recently, the CSC hypothesis has gained credibility within
the cancer research community [1–5]. In its simplest version,
this hypothesis postulates that most tumors (if not all) arise by
consecutive genetic changes in a small subpopulation of cells
that have intrinsic characteristics similar to those of normal
stem cells (SCs) [6–9]. A fast growing body of experimental
evidence suggests that these so-called cancer stem cells (CSCs)
are the drivers of cancer and are responsible for sustained
tumor growth. Although no general consensus has yet been
reached on several key aspects of the biology of CSCs, there is
agreement in some of their distinctive features: (a) self-renewal
capabilities, (b) potential for differentiation into the various cell
subtypes of the original cancer, and (c) increased tumorigenesis
[9–14].
Numerous researchers have reported the existence of CSC
subpopulations in solid tumors [15–25]. CSCs have been reported
to be more resistant to normal cancer therapies than are
differentiated tumor cells (bulk tumor cells) [18,19,22,25,26].
Therefore, properly and selectively targeting CSCs could be one of
the main lines of attack in a new wave of therapeutic strategies
against cancer [5,22,27–29].
Although tumor growth has been a subject of intensive
mathematical modeling in the last two decades, the concept of
existence of a CSC population within tumors has been only
recently included as an element in describing tumor growth [30–
45]. Among these examples, different modeling approaches have
been used, ranging from stochastic [35,42,45] to deterministic
modeling [37,41]. CSC-cancer modeling has frequently focused
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instance, Dingli and Michor [36] used mathematical modeling to
demonstrate the importance of selective targeting of CSCs to
improve the efficiency of cancer therapies. Similarly, Ganguly and
Puri [39] formulated a model to evaluate chemotherapeutic drug
efficacy in arresting tumor growth, based on the cancer stem cell
hypothesis. Their results suggested that the best response to
chemotherapy occurs when a drug targets abnormal stem cells.
CSC based mathematical models have also been used to forecast
the effect of specific therapeutic agents (and combinatory
therapies). Several contributions have explored different aspects
of the treatment with imatinib [37,41,43]. Mathematical modeling
has also been used to gain understanding of fundamental issues
underlying CSC biology [31,32,40,42,44,45]. The biology of
CSCs has not been fully elucidated and many questions still
remain unresolved [16,45]. In particular, some of these uncer-
tainties are related to the dynamics of tumor growth. As an
illustration, little is known about the balance between the multiple
and complex cellular events that occur during the early stages of
tumor progression. One of the central objectives of this work is to
identify if some commonalities (or universal features) may exist
with respect to the kinetics of early tumor growth. Experimentally
studying the balance between the different cellular events involved
on the process of tumor growth is not a trivial matter.
Mechanistically based mathematical modeling might be highly
useful for simulating the dynamics of cancer initiation and
progression, the response to different therapies, and the evolution
of resistance to drugs [30], as well as for gaining further
fundamental understanding on the underlying dynamics of tumor
growth.
In the present manuscript, we present a simple mathematical
model that is designed to study the role of CSCs in tumor
growth, with the aim of understanding the kinetic relationships
between the different processes leading to exponential growth in
solid tumors and evaluating possible therapeutic strategies for
cancer treatment. We attempted to capture the key features of
the known biological behavior of CSCs in a pseudo-chemical
model, where cell division and death of the three cell subtypes
considered are represented as ‘‘chemical reactions.’’ The
intrinsic rates at which these reactions (cellular events) occur
are the parameters of the model (kj) and are analogous to
reaction rate kinetic constants. Based on an exploration of the
parameter space of these kinetic constants, we derive conclu-
sions related to their relative magnitudes. Some inferences
regarding the fundamental biology of tumor growth and the
effectiveness of some therapeutic strategies against cancer are
discussed.
Methods
A pseudo-chemical model for tumor growth: underlying
biological concepts
Tumors are a heterogeneous mix of cells, some of which exhibit
SC-like characteristics [14,16,17,34,46–48]. It is probably more
accurate to say that a tumor possesses a continuous spectrum of
cell types, ranging from CSCs to more differentiated cells. In most
of the previous modeling studies, the complexity of tumor tissue
has been addressed by defining several cell subpopulations
(typically from two to four), leading to compartment models
[31,32,37,40]. In order to reduce the complexity of the resulting
model, only three subtypes of cells are considered: CSCs, transit
amplifying progenitor cells (P), and terminally differentiated cells
(D) (Fig. 1). This assumption is consistent with several experimen-
tal reports that simplify the cell heterogeneity found in cancer, in
which three main cell subtypes are indentified [23,48] with some
variants in nomenclature; i.e., holoclones, meroclones, and
paraclones [49–51].
In our model, events related to CSC self-renewal, to maturation
of CSCs into P cells, to further differentiation to D cells, and to
death of all cell subtypes, are represented as ‘‘chemical reactions’’
and are mediated by specific rate constants. These reactions occur
in a system that has no nutrient limitations during the phase of
exponential tumor growth. This assumption presumes that
angiogenesis occurs at a rate that ensures the accessibility of
nutrients sustain constant growth.
Framed in this way, the time evolution of all cellular
subpopulations can be represented by a set of ordinary differential
equations that have an analytical solution. In the following
paragraphs, we introduce each of the cellular events considered for
the construction of the model, and their representation in the form
of ‘‘chemical reactions.’’
Expansion of SCs can be accomplished through symmetric
division [52,53], whereby one CSC originates two CSCs:
CSC  
k1 {?2CSC ðR1Þ
Alternatively, a CSC can undergo asymmetric division (whereby
one CSC gives rise to another CSC and a more differentiated
progenitor (P) cell). This P cell possesses intermediate properties
between CSCs and differentiated (D) cells [2,51,54–56]:
CSC  
k2 {?CSCzP ðR2Þ
Both symmetrical and asymmetrical cell divisions of CSCs have
been experimentally documented by staining of nuclear Oct-4 (a
stem cell marker) [57]. Regulation of the ratio between symmetric
and asymmetric division might possibly be crucial for the
development and progression of cancer [44,52].
CSCs may also differentiate to P cells by symmetric division
[44,58]:
CSC  
k3 {?2P ðR3Þ
P cells can either self-renew, with a decreased capacity compared
to CSCs, or they can differentiate to D cells [21,31,59,60]:
P  
k4 {?2P ðR4Þ
P  
k5 {?2D ðR5Þ
D cells do not have the capacity to proliferate [20,51,62], so their
corresponding kinetic constant should be very small (here
considered negligible). In addition, all cellular subtypes can
undergo cell death:
CSC  
k6 {?M ðR6Þ
P  
k7 {?M ðR7Þ
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k8 {?M ðR8Þ
To establish the model, we followed a classical strategy used in
chemical reaction engineering to describe a system of chemical
reactions. For each cellular event, a ‘‘reaction rate’’ can be
successively established: r1=k1CSC; r2=k2CSC; r3=k3CSC;
r4=k4P; r5=k5P; r6=k6CSC; r7=k7P; r8=k8D.
Neglecting all terms related to transport of cells (to and from the
tumor), the rate of accumulation of a cell subtype ‘‘j’’, dj/dt,i s
equivalent to the net generation of that cell subtype, given by the
addition of all reaction rates where that cell subtype is involved (i.e.
produced or consumed).
For example, the cell species CSC is involved in the cellular
events R1, R2, R3, and R6. In reaction R1, CSC is produced at a
rate equivalent to 2r1, and consumed at a rate r1. In the cellular
event R2, CSC is produced at a rate r2, and consumed at the very
same rate r2. In the cellular event R3, CSC is consumed at a rate
r3 due to differentiation into P. Similarly, in the cellular event R6,
CSC is consumed at a rate r6 due to cell death.
The accumulation of CSCs within the system will be given by
Eq. 1:
dCSC
dt
~2r1{r1zr2{r2{r3{r6
dCSC
dt
~r1{r3{r6
dCSC
dt
~k1CSC{k3CSC{k6CSC
dCSC
dt
~ k1{k3{k6 ðÞ CSC
ð1Þ
Similarly, the accumulation of P and D cells within the system is
expressed as:
dP
dt
~r2z2r3z2r4{r4{r5{r7
dP
dt
~k2CSCz2k3CSCz2k4P{k4P{k5P{k7P
dP
dt
~ k2z2k3 ðÞ CSCz k4{k5{k7 ðÞ P
ð2Þ
And,
Figure 1. Basic assumptions of the model. (A) Different cell populations are found in solid tumors. For simplicity, the model considers only three
cell compartments or differentiation stages (CSC=Cancer Stem Cells, P=progenitor cells, D=terminally differentiated cells, and M=dead cells). All
the possible different stages of differentiation of progenitor cells (P1, P2, etc., have been lumped into the cell subtype P. CSC, P, and D cell subtypes
undergo cell death through reactions R6, R7, and R8 respectively. (B) Cellular division events considered in the model: symmetrical self-renewal of
cancer stem cells (R1); asymmetrical renewal of cancer stem cells (R2); symmetrical differentiation of cancer stem cells into progenitor cells (R3);
symmetrical proliferation of progenitor cells (R4); and symmetrical differentiation of progenitor cells into fully differentiated cells (R5).
doi:10.1371/journal.pone.0026233.g001
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dt
~2r5{r8
dD
dt
~2k5P{k8D
ð3Þ
This simple system of ordinary differential equations can be
analytically solved to obtain the populations of each cell type
(CSC, P, D) at any time, provided that a set of initial cell
populations is specified (CSCo, Po and D).
CSC~CSC0eat ð4Þ
P~CSC0 b= a{x ðÞ ½  eatz½P0{CSC0b= a{x ðÞ   ext ð5Þ
D~deatzeextz D0{d{e ðÞ e{k8t ð6Þ
Where
a~k1{k3{k6 ð7Þ
b~k2z2k3 ð8Þ
x~k4{k5{k7 ð9Þ
d~2k5CSC0b= a{x ðÞ a{k8 ðÞ ½  ð 10Þ
e~2k5 P0{CSC0b= a{x ðÞ ½  = x{k8 ðÞ ð 11Þ
The total number of tumor cells (N) will be the sum of the three
cellular subtypes, assuming that dead cells are reabsorbed:
N cells ðÞ ~CSCzPzD ð12Þ
The tumor volume can be calculated, considering that the effective
volume contribution of a spherically shaped cell in a spherical
tumor is 4.18610
26 mm
3/cell [62], as:
Vm m 3 
~4:18|106N ð13Þ
This assumption implies that the tumor grows at constant cellular
density, which might be reasonable during exponential tumor
growth, when we have assumed that no nutrient transport
limitations exist, and space constraints are not significant [63].
Results and Discussion
Significance of the parameters and constraints of the
model
The model has one kinetic parameter per cellular event (or
‘‘reaction’’). A brief discussion of the physical significance of these
kinetic constants is pertinent here. In a typical elementary
chemical reaction, the rate of appearance of a chemical species
is proportional to the concentration of the reagents through a
proportionality constant, the specific rate of reaction. Analogously,
for our cellular system, the ‘‘rate of reaction’’ of each cellular event
depends on both the number of precursor cells for that event and
the proportionality constant kj that will multiply that number. For
example, the rate of disappearance of CSCs, due exclusively to the
occurrence of the cellular event R1, is r1, and is mediated by the
kinetic parameter k1. Therefore, k1 is an intrinsic reaction rate
constant that indicates the natural predisposition of a cell, in this
case a CSC, to divide symmetrically to originate two CSCs. In our
model definition, kj is not equal to the growth rate of a cell subtype,
but rather to the intrinsic proliferation rate associated with the
frequency at which that particular cell subtype generally divides.
To calculate the rate of accumulation of a particular cellular
species (or net growth rate of that species), all terms where this
species appears or disappears should be considered. For example,
for the particular case of CSC, the associated rate of accumulation
involves r1,r 3, and r6 (see equation 1).
Kinetic parameter grouping
The proposed kinetic model has eight independent variables.
We simplified the analysis of the parameter space by grouping the
eight kinetic constants of the model into three groups. Group I
includes k1, k2, and k3; kinetic constants associated with cellular
events that relate to CSC proliferation and differentiation. Group
II includes k4 and k5, since they mediate cellular events related to
proliferation or differentiation of P cells. Finally, k6, k7 and k8 were
included in Group III, as they describe cell death of each cell
subtype.
In addition, some mathematical relationships among parameter
groups and kinetic constants were defined. The value of k1, the
rate constant for symmetric CSC renewal, was set equal to one.
This is convenient, since all the rest of the kj values can now be
defined (or scaled) relative to k1. In addition, it is helpful to define
ratios between the kinetic parameters, namely W2/1, W3/1, W4/1,
W5/4, W6/1, W7/1, and W8/1. For example, W4/1 is the ratio between
k4/k1; biologically, it reflects the relative magnitude of the intrinsic
kinetic constant governing symmetrical division of progenitor cells
with respect to that related to symmetrical division of cancer stem
cells. Similarly, W5/4 (k5/k4) indicates the relative magnitude
between the rate constants associated to symmetrical division of
progenitor cells to render two progenitor cells (R4) and
symmetrical division of progenitor cells to produce two differen-
tiated cells (R5). In this way, a vector of Wi/j values will define a
complete set of kj values, and therefore a biological scenario for
tumor growth. Illustratively, once k1 is set to the unit value (k1=1),
the vector Wi/j=[W2/1, W3/1, W4/1, W5/4, W6/1, W7/1, W8/1]=[1.0,
0.01, 5.35, 0.8, 0.01, 0.1, 1.0] defines a scenario where k1=1,
k2=1.0, k3=0.01, k4=5.35, k5=4.28, k6=0.01, k7=0.1, k8=1.0.
Although, a priori, all kj values are plausible, some constraints
based on biological knowledge can be applied. For instance, in the
present paper, the intrinsic apoptosis rate was considered to
increase as cells become progressively more differentiated.
Consequently, the greatest death rate corresponds to the most
differentiated phenotype (D). On the other hand, CSCs have an
extremely low apoptotic index [21,53,64–66]; therefore, the next
constraints will be imposed for all simulations:
k6vk7; and k7vk8 ð14Þ
In addition, experimentally, a minimum fraction of CSCs has been
found to be maintained through the evolution of cancer [20,61].
Normally, this fraction is lower than 1% of the total cell number
[20,25,67]. Therefore, CSC/N,0.01 and d[CSC/N]/dt<0 for
all times. Finally, the fraction of P cells can be estimated from
Model Based on the Cancer Stem Cell Hypothesis
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also well known that D cells constitute the majority of tumor cells
[7,20,37]. Accordingly, we set the following expressions as
constraints:
P=N&0:2 and D=N&0:8 ð15Þ
The biology of CSCs has not been fully elucidated and many
questions still remain unresolved [16,45]. In particular, some of
these uncertainties are related to the dynamics of tumor growth.
As an illustration, little is known about the balance between the
multiple and complex cellular events that occur during the early
stages of tumor progression. One of the central objectives of this
work is to identify if some commonalities (or universal features)
may exist with respect to the kinetics of early tumor growth.
Experimentally studying the balance between the different cellular
events involved on the process of tumor growth is not a trivial
matter.
The simple model that we proposed here allows for the study of
the effect of variations in the relationships between the intrinsic
kinetic values of each one of the cellular events defined (from R1 to
R8). In our discussion, we place particular importance on the
experimentally documented fact that the CSC fraction in a tumor
is constant during tumor evolution, which is clear evidence of the
crucial role of the CSC reservoir in tumor growth [20,22,25,51].
Therefore, the constraint d[CSC/N]/dt<0 becomes central to
identifying biologically consistent and feasible solutions for the
model.
Feasible model solutions
In principle, one would expect that a vast number of
combinations would render dynamical behaviors that would be
consistent with experimental observations of the evolution of solid
tumors. Based on our experience testing the model, the imposed
constraints (namely d[CSC/N]/dt<0; P/N<0.2; D/N<0.8;
CSC/N,0.01) substantially limit the number of sets of parameter
values that lead to feasible solutions.
As an illustration, let us consider the particular solution,
obtained when the vector Wi/j=[W2/1,W3/1,W4/1,W5/4,W6/1,W7/1,
W8/1]=[1.0, 0.01, 5.35, 0.8, 0.01, 0.1,1.0] is used. This scenario
corresponds to one where k1=1, k2=1.0, k3=0.01, k4=5.35,
k5=4.28, k6=0.01, k7=0.1, k8=1.0. The corresponding solution
exhibits exponential growth, typically observed during the first
stage of tumor growth (Figure 2A). After 30 arbitrary time units, all
constraints are satisfied; namely, d[CSC/N]/dt<0; P/N<0.1875;
D/N<0.8106; CSC/N<0.0018 (Figure 2B). Indeed, while
exploring feasible solutions, we found the CSC/N vs. time plot
to be particularly useful (see Figure 2C). For example, Figure 2C
shows the dependence of the dynamics of CSC/N with respect to
the value of W4/1. In this illustrative exercise, the rest of the Wi/j
values remain constant, while W4/1 was progressively increased
within the range of 5.0 to 5.7 units. Only specific value of
W4/1=5.35 satisfied the condition of d[CSC/N]/dt=0. Around
the solution defined by the vector Wi/j=[1.0, 0.01, 5.35, 0.8, 0.01,
0.1, 1.0] other solutions exist that also satisfy d[CSC/N]/dt=0;
some of these have different CSC/N, P/N, and D/N steady state
values. We found identification of these to be aided by trial and
error investigations of the effect that small perturbations to this set
of Wi/j values had on the quality of the solutions. Table 1 presents
results from a series of simulation experiments where Wi/j values
were varied around those that produced the solution previously
discussed (Exp 0 in Table 1).
Some solutions, although satisfy d[CSC/N]/dt=0, differ
importantly in terms of their resulting cellular fractions at the
steady state. For example, the solution of Exp. 7 (Table 1) is
conducive to a steady state in which the cellular fractions CSC/N,
P/N, and D/N are 0.0459, 0.1703, and 0.7836, respectively. In
this particular case, the modification consisted of increasing the
value of W5/4 (or k5/k4) from 0.80 to 0.85. This implies an increase
of only 6.25% in the value of the intrinsic reaction rate constant of
differentiation versus self-renewal of the subpopulation of
progenitor cells. Not intuitively, the fraction of cancer stem cells
Figure 2. Model output. (A) The model estimates the time evolution
of each one of the cell subpopulations considered, fully differentiated
cells (D; blue line); progenitor cells (P; red line); and cancer stem cells
(CSC; green line). (B) by plotting the cell fractions for each cell
population (D/N; blue line), (P/N; red line), and (CSC/N; green line), it is
possible to search for feasible and biologically consistent solutions (i.e.
d[CSC/N]/dt=0; C/N,0.01). (C) Only a relatively small set of parameter
combinations result in solutions that satisfy the constraint d[CSC/N]/
dt=0. The solution defined by the vector Wi/j=[1.0, 0.01, 5.35, 0.8, 0.01,
0.1, 1.0] satisfy d[CSC/N]/dt=0 only if when the specific value of
W4/1=5.35 was used (green line). Values of W4/1=k4/k1.3.5 (purple and
light blue line) cause d[CSC/N]/dt,0; and values of W4/1=k4/k1,3.5 (red
and dark blue line) cause d[CSC/N]/dt.0.
doi:10.1371/journal.pone.0026233.g002
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differentiated cells induced by their higher cell numbers
(r8=k8[D].r7=k7[P].r6=k6[CSC]).
Other sets produce solutions with steady states similar to those
of our reference case, previously mentioned (Wi/j=[1.0, 0.01,
5.35, 0.8, 0.01, 0.1, 1.0]; experiment 0 in Table 1). For example,
the set Wi/j=[1.5, 0.005, 5.35, 0.8, 0.01, 0.1, 1.0] also produces a
solution that satisfies d[CSC/N]/dt=0, with a steady state
characterized by the cellular fractions P/N<0.1878; D/
N<0.8102; CSC/N<0.0018 (Figure 3A, Exp. 15 in Table 1).
We found several solutions (see Exp. 15, 16, and 17 in Table 1),
with steady state values in the vicinity of P/N<0.18, D/N<0.81,
and CSC/N<0.0018, by modifying the value of two of the
parameters Wi/j with respect to the values of the reference set
(Exp. 0 in Table 1). To do so, we selected displacements (DWi/j)
with opposite effects on the steady state P/N or CSC/N values
(according to column No. 10 in Table 1). For example, in Exp.
15, an increase of 50% on the value of W2/1 was compensated by
a proportional decrease (50%) on the value W3/1. This was an
expected result: an increase in the rate of asymmetrical
differentiation (r2) has to be balanced by a decrease in the rate
of symmetrical differentiation (r3). Similarly, the opposite
statement should hold. A decrease of 20% in the intrinsic rate
of asymmetrical differentiation was compensated by a 20%
increase in the rate of symmetrical differentiation (Exp. 16 in
Table 1). Less intuitively, in Exp. 17 (see Figure 3B), an
increment in the W2/1 value was balanced by a decrease on
W4/1. In this case, a 50% increase in the rate of asymmetrical
differentiation is equilibrated by a minor decrease (0.5%) in the
intrinsic rate of both symmetrical proliferation (r4) and differen-
tiation of progenitor cells (r5). Note that both the value of k4 and
k5 are influenced by W4/1, since the value of W5/4 was left
unmodified.
Kinetic commonalities during exponential growth
While multiple sets of Wi/j could produce results consistent with
the proposed set of constraints, those sets must comply with some
general characteristics. For example, as illustrated before, the
parameters W2/1 and W3/1 (and consequently k2 and k3) are
inversely related. To keep the overall fraction of cancer stem cells
CSC/N constant over time, an increase on the value of k2 must be
balanced by a proportional decrease on k3, and vice versa.
This observation suggests a fine feedback biochemical control,
and not necessarily a fixed ratio k2/k3. This result is relevant, since
the experimental determination of the relative probability of
occurrence of symmetric and asymmetric CSC division is difficult.
The suggestion that regulation of the ratio between symmetric and
asymmetric division may be crucial for the development and
progression of cancer appears recurrently in the literature
[33,46,52,54,55]. For example, Boman et al. [31], using a
compartmental model, concluded that the only mechanism that
can explain how CSC subpopulations can increase exponentially
during colorectal cancer development involves an increase in
symmetric SC cell division. This finding suggests that systemic
therapies for effective treatment of cancers must act to control or
eliminate symmetrical cancer SC division in tumors, while
minimally affecting normal SC division in non-tumor tissues. In
this respect, Turner et al. [45] have consistently concluded that
symmetric division rates are the key in dictating brain tumor
composition. Their results also suggested the importance of
developing novel treatment strategies that specifically target the
CSC subpopulation in brain tumors.
Table 1. Analysis of the effect of small perturbations around a particular solution.
Exp W1/1 W2/1 W3/1 W4/1 W5/4 W6/1 W7/1 W8/1 d[CSC/N]/dt (*) CSC/N @ss P/N @ss D/N @ss
0 1 1 0.01 5.35 0.8 0.01 0.1 1 ss 0.0018 0.1875 0.8106
1 1 1.5 0.01 5.35 0.8 0.01 0.1 1 (2) 0.1878 0.8105
2 1 0.5 0.01 5.35 0.8 0.01 0.1 1 (+) 0.1871 0.8107
3 1 1 0.015 5.35 0.8 0.01 0.1 1 (2) 0.1874 0.8108
4 1 1 0.005 5.35 0.8 0.01 0.1 1 (+) 0.1875 0.8103
5 1 1 0.01 5.45 0.8 0.01 0.1 1 (2) 0.186 0.8128
6 1 1 0.01 5.25 0.8 0.01 0.1 1 (+) 0.1891 0.807
7 1 1 0.01 5.35 0.85 0.01 0.1 1 ss 0.0459 0.1703 0.7836
8 1 1 0.01 5.35 0.75 0.01 0.1 1 ss 0 0.218 0.7819
9 1 1 0.01 5.35 0.8 0.1 0.1 1 (2) 0.1871 0.8127
10 1 1 0.01 5.35 0.8 0.001 0.1 1 (+) 0.1876 0.81
11 1 1 0.01 5.35 0.8 0.01 1 1 ss 0.1435 0.1608 0.6955
12 1 1 0.01 5.35 0.8 0.01 0.01 1 (2) 0.194 0.8057
13 1 1 0.01 5.35 0.8 0.01 0.1 10 ss 0.0055 0.5588 0.4356
14 1 1 0.01 5.35 0.8 0.01 0.1 0.1 ss 0.0011 0.1119 0.8869
15 1 1.5 0.005 5.35 0.8 0.01 0.1 1 ss 0.0018 0.1878 0.8102
16 1 0.8 0.012 5.35 0.8 0.01 0.1 1 ss 0.0018 0.1873 0.8107
17 1 1.5 0.01 5.325 0.8 0.01 0.1 1 ss 0.0018 0.1882 0.8098
(*) ss indicates that the solution reaches a steady state d[CSC/N]/dt=0 in less than 30 arbitrary time units; (+) indicates that d[CSC/N]/dt.0 after 30 arbitrary time units;
(2) indicates that d[CSC/N]/dt,0 after 30 arbitrary time units.
Rows corresponding to experiments 1 to 14 were built by varying only one Wi/j value at a time, while the rest were kept constant with respect to the reference case (Exp.
0). Column 10 indicates whether the CSC/N fraction reaches a steady state; that is, (d[CSC/N]/dt)=0. If that is the case, the CSC/N fraction is indicated in column 11.
doi:10.1371/journal.pone.0026233.t001
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results suggest that the ratio k4/k1 has to be maintained in a very
narrow band in order to sustain exponential tumor growth with
constant CSC/N, P/N, and D/N fractions. For example, in our
model, for the case where CSC/N<0.0018, P/N<0.18, and D/
N<0.81, the ratio k4/k1 must be maintained at <5.35. Variations
of less than 2.5% around this value must be compensated, for
example, by important modifications to the value of k2 (or more
generally stated W2/1; see Figure 4A) or alternatively, k3 (or more
generally stated W3/1; Figure 4B).
We observed similar situations for steady states (d[CSC/N]/
dt=0) defined by different CSC/N, P/N, and D/N fractions. For
example, the vector Wi/j=[1.5, 0.005, 3.6, 0.75, 0.01, 0.1, 1.0]
produces a solution where d[CSC/N]/dt=0, with CSC/
N<0.045, P/N<0.25, and D/N<0.70. Small variations in
W4/1=k4/k1=3.6 disrupt the d[CSC/N]/dt=0 condition, unless
they are accompanied by an important adjustment to k2. Notice,
however, that a 4.5% increase in CSC in a solid tumor is not
consistent with previously reported experimental data. We could
only find steady states (d[CSC/N]/dt=0) with CSC/N,0.01, P/
N<0.20, and D/N<0.80 when W4/1=k4/k1 was in the range of
5.18 to 5.40 (See Figure 4).
Indeed, we found a perfect linear correlation between the values
of W4/1 and W2/1 that fulfill the conditions d[CSC/N]/dt=0,
CSC/N,0.0018, P/N<0.20, and D/N<0.80, namely W2/1=
219.997W4/1+107.98 (Figure 4A). An analogous linear relation-
ship exists between W4/1 and W3/1, namely W3/1=20.1947W4/1+
1.0515 (Figure 4B). This suggests that the relative magnitude of the
proliferation and differentiation rate constants for progenitor cells
(k4+k5) must be at least half an order of magnitude above the
analogous parameters for stem cells (CSC) in order to maintain
exponential tumor growth while keeping (d[CSC/N]/dt=0). Our
results also suggest that the ratio between the intrinsic constant
rate for symmetric proliferation of progenitor cells and the
analogous parameter for stem cells symmetric self-renewal
(W4/1=k4/k1) should be approximately half an order of magnitude
(between 5.10 and 5.4), independently of the values of k2 and k3.
We also observe that, to maintain tumor growth, the constant for
symmetric cancer stem cell renewal should be in the same order of
magnitude as the sum of k2 and k3.
The time evolution of the rates of proliferation of CSCs,
progenitors, and terminally differentiated cells (dCSC/dt, dP/dt,
and dD/dt respectively) can be calculated using equations (1), (2),
and (3). Despite the fact that the kj values associated with CSC
events are of the order of magnitude, and in some cases even
higher, than kj values corresponding to P and D cells, the number
Figure 3. Feasible solutions for the model. Within the explored
parameter space, once a feasible steady state solution is found, others
can be found on the vicinity of a specific vector Wi/j. (A) Solution for the
vector Wi/j=[1.5, 0.005, 5.35, 0.8, 0.01, 0.1,1.0]. (B) Solution for the vector
Wi/j=[1.5, 0.01, 5.325, 0.8, 0.01, 0.1, 1.0].
doi:10.1371/journal.pone.0026233.g003
Figure 4. Linear relationships between model parameters.
Certain linear relationships between CSC self-renewal and differentia-
tion kinetic parameters allow identification of families of feasible
solutions: (A) By increasing W2/1 while proportionally decreasing W4/1 a
family of feasible model solutions can be found. Similarly, (B) W3/1 and
W4/1 are linearly related.
doi:10.1371/journal.pone.0026233.g004
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differentiated cells. Consequently, the product (k1CSC) and the
global rate of proliferation (dCSC/dt) are one or two orders of
magnitude smaller than those rates for more differentiated cells
during all stages of the exponential growth of a tumor. In addition,
early in the development of a tumor, the ratios between the global
growth rates of the different cell subtypes achieve equilibrium.
According to our simulation results, (dP/dt)/(dCSC/dt)<100 and
(dD/dt)/(dP/dt)<4. Therefore, (dD/dt)/(dCSC/dt)<400. This equi-
librium of growth rates between cell subtypes must be achieved if
balanced tumor growth is to maintain constant ratios of cell
subpopulations. Again, these ratios between growth rates of
different cell subpopulations are not easy to calculate in vivo.
The role of cell death
The model is sensitive to the ratios between cancer stem cell
self-renewal and cell death (W6/1, W7/1, W8/1). The initial
assumption of k6,k7,k8 should be satisfied in order to observe
constant cell fractions throughout exponential growth. This is
consistent with several experimental reports. For instance, it has
been observed that the apparent rate of death in prostate CSC is
much lower than in other tumor cell subtypes [20,51]. We also
found that the W6/1, W7/1, W8/1 values should be in the range of
0.01 to the same order of magnitude as k1 (W8/1<1) to produce
solutions where d[CSC/N]/dt=0 and CSC/N,0.01. Provided
that these two criteria are satisfied (k6,k7,k8 and W8/1<1),
families of solutions satisfying d[CSC/N]/dt=0 and CSC/
N,0.01, but with different P/N and D/N values, can be
obtained. For example, Figure 5 presents one of these solution
families, where k1=1 and vector Wi/j was initially set as Wi/j=
[080, 0.012, 5.35, 0.8, 0.01, 0.1, 1.0] to locate a first condition
satisfying d[CSC/N]/dt=0 and CSC/N,0.01. Other points of
the same series can be found by trial and error, by progressive (and
proportional) changes in the W6/1 and W7/1 values while keeping
the rest of the parameters constant. Specifically, we identified an
entire family of solutions that obeys the linear relationship
W7=W6+0.09. As the W6/1 and W7/1 values increase, the CSC
fraction decreases from 0.0018 to 0.00125, and the fraction of
differentiated cells increases from 0.8107 to 0.8725.
Model fitness to experimental data sets
The model is flexible enough to allow proper adjustment to a
wide range of possible tumor growth scenarios. Here, to validate
the model, we selected three different tumor growth experimental
data sets available from previous literature [13,25,69]. In all cases,
the same Wi/j vector was used to describe the ratios between the
kinetic parameters of the model, namely Wi/j=[W2/1, W3/1, W4/1,
W5/4, W6/1, W7/1, W8/1]=[1.0, 0.01, 5.35, 0.8, 0.01, 0.1, 1.0]. After
proper scaling of the y axes (by multiplying by a different scaling
factor in each case), the model reproduces the three experimental
data sets with an R-square greater than 0.97 (Figure 6). This
suggests that, although the values for the intrinsic kinetic rates of
each tumor might be different, the relationships between them (all
Wi/j values) could be approximately common among different
cancer types. For all simulations, all constraints were satisfied for
each set of experimental data, particularly the condition of a
constant CSC cell fraction lower than 1% (specifically 0.0018).
We should emphasize that our model is capable of reproducing
the evolution of tumor growth only during its exponential phase.
For the experimental sets that we had analyzed, this means up to a
size of 1500 mm
3; clinically, a medium size solid tumor. Tumors
of this size quite often contain necrotic tissue at their central core.
Our model does not distinguish between living and dead tissue,
and only provides an overall volume based on a very naive and
simple approximation of equal spherical volume contribution of
each cell (dead or alive) within the tumor. Although simple and
unrealistic, this assumption has yielded a good agreement with
experimental sets for our descriptive purposes.
Contrasting strategies to combat cancer
Most of the currently used chemotherapy and radiotherapy
strategies against cancer are unable to distinguish between
different tumor cell types, or even healthy and tumor cells, killing
them all unselectively. Some reports also indicate that CSCs are
particularly resistant to conventional therapeutic procedures
[18,19,23,26,51]. Friel et al. [19] reported that CSCs isolated
from human EnCa were particularly resistant to Paclitaxel, a
widely used chemotherapeutic anticancer agent. Kang et al. [18]
found that CSCs from GBM were radio-resistant when exposed to
radiation dosages that killed other tumor cell subpopulations.
Eyler and Rich [26] and Dylla et al. [23] reported additional
evidence of CSC resistance to conventional therapies. More
recently, Tan et al. demonstrated that holoclone forming cells
from pancreatic tumors (with stem cell characteristics) exhibit
much higher chemoresistance to gemcitabine and 5-FU than
meroclones and paraclones [51].
This enhanced resistance of CSCs would explain the observed
aggressive regeneration of tumors after treatment. The remaining
CSC population would grow exponentially (having an abundant
amount of nutrients) and would readily regenerate the other
subpopulations that form the bulk of the tumor.
Figure 7A shows the behavior of a solid tumor when treated
with a non-specific therapy such that 90%, 99%, 99.9% or
99.99% of the solid tumor cells are eradicated at a particular time,
let us say 120 days. For illustrative purposes, the base case we have
chosen is the case illustrated in Figure 6C [13]. In all instances,
after an incubation time, the tumor relapses to exhibit practically
the same progression profile originally followed. Even in the case
of the most effective treatment, which kills 99.99% of all tumor
Figure 5. Linear relationships between model parameters. The
intrinsic apoptotic rates of CSC and P cells are also linearly related.
Proportional increases in W6/1 and W7/1 can reveal a family of feasible
model solutions.
doi:10.1371/journal.pone.0026233.g005
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growth in a relatively short time (within 50 days).
An intuitive therapy to eradicate tumors, widely suggested in
recent literature [22,23,24,26–29,31,46,70–72], relates to the
targeting of CSCs, killing them selectively through treatment
(i.e., augmenting k6 significantly over k7, and k8) or, alternatively,
preferentially killing stem cells at a particular time. Other authors
have evaluated this strategy using mathematical models; for
example, Dingli and Michor [36] designed a simple mathematical
model to demonstrate the importance of eliminating tumor stem
cells. The authors explored different therapeutic scenarios to
illustrate the properties required in novel anti-cancer agents for
successful tumor treatment. Their results indicated that successful
therapy must eradicate tumor stem cells. Similarly, Ganguly and
Puri [39] formulated a mathematical model to evaluate chemo-
therapeutic drug efficacy in arresting tumor growth based on the
cancer stem cell hypothesis. Their results also suggest that the best
response to chemotherapy occurs when a drug targets abnormal
stem cells.
However, our simulations show that this therapeutic avenue,
although superior to unselective treatments, is only effective if
progenitor cells (P) are also targeted. This is, for the time window
that our model is applicable, the exponential tumor growth phase,
both cancer stem cells and progenitor cells have to be eradicated to
stop tumor growth. This can be easily seen by examining equation
2[ dP/dt=(k2+2k3)CSC+(k42k52k7)P ]. In that equation, the rate
of accumulation of the subpopulation of progenitor cells depends
on two terms, one affected by the number of CSCs and the other
dependent on the number of P cells. Therefore, even in the
complete absence of CSCs, the term depending on P has to be
negative for P to decrease. That term, namely (k42k52k7)P, can
only be negative if k4 ,k5+k7. For the set of Wj/i values that we
have chosen (based on the rational that we had explained before:
d[CSC/N]/dt=0 with CSC/N,0.01) this condition is not met.
Figure 6. Three experimental data sets, corresponding to the
different scenarios referred to in the text, were used to
validate the model. A comparison between the experimental data
(N black circles) and the model curve-fit (yellow solid line) is provided
for each set. The CSC/N fraction (blue line) and P/N fraction (red line) are
plotted for each experimental scenario. For each simulation, the vector
Wi/j=[W2/1, W3/1, W4/1, W5/4, W6/1, W7/1, W8/1]=[1.0, 0.01, 5.35, 0.8, 0.01,
0.1, 1.0] was multiplied by a different scaling factor (17.56Wi/j; 5.06Wi/j;
and 7.06Wi/j respectively). (A) A human prostate tumor transplanted
into a mouse model [69]; it is assumed that the original percentage of
CSCs was 1%; (B) 2000 CSCs from a breast primary tumor implanted in
NOD/SCID mice [25]; and (C) 1610
5 colon CSCs isolated and implanted
in NOD/SCID mice [13]. For all simulations, the vector Wi/j=Wi/j=[W2/1,
W3/1, W4/1, W5/4, W6/1, W7/1, W8/1]=[1.0, 0.01, 5.35, 0.8, 0.01, 0.1, 1.0] was
used.
doi:10.1371/journal.pone.0026233.g006
Figure 7. Different strategies against tumor progression are
explored using the proposed model. (A) The progression of a
tumor without intervention [15] is depicted from day 0 to day 120
(black circles and yellow curve). Different percentages of all tumor cells
(CSC, P and D) are unselectively eradicated at day 120: 90% (yellow line);
99% (blue line); 99.9% (orange line) and 99.99% (green line). The CSC/N
fraction (blue line) and P/N fraction (red line) remain unaltered for all
unselective treatments. (B) Effective alternative therapeutic strategies to
treat cancer might include enhancement of differentiation over CSC
self-renewal: i.e., 10% increase in W5/4 (yellow line) or 15% increase in
W4/1 (green line). The CSC/N fraction (blue line) and P/N fraction (red
line) are plotted for the case of a 15% increase. The case where 99.9% of
all tumor cells are eradicated unselectively at day 120 is included as a
reference (orange line).
doi:10.1371/journal.pone.0026233.g007
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progenitor subpopulation to effectively detain tumor progression
has been suggested before in literature [73], also at the light of a
mathematical argument.
Conceivably, in the long term, selective killing of all cancer
stem cells will be sufficient to eradicate the tumor, since CSCs
are the ultimate cell reservoir responsible for sustained growth.
At the end of exponential growth phase, the relative weight of k7
has to increase (or alternatively the ratio W5/4=k5/k4 will
change) due to causes such as oxygen mass transfer or nutrient
limitations. We plan to include this functionality in a later
version of our model.
This last comment on the relative ratio W5/4=k5/k4 is useful to
introduce a less intuitive therapeutic strategy. Promotion of
differentiation has been suggested for clinical practice [74,75].
Using the proposed model, we explored variants of this approach.
Indeed, augmenting W5/4=k5/k4 appears to be therapeutically
promising. In biological terms, this means increasing the relative
intrinsic rate of progenitor cell differentiation with respect to the
rate of progenitor cell renewal. Interestingly, a very modest 10%
increase in W5/4 (from 0.8 to 0.9), while keeping the rest of the Wi/j
values fixed, retards tumor relapse more effectively than does the
unselective tumor treatment (see Figure 7B). Similarly, increasing
the ratio W4/1=k4/k1 and promoting a tumor richer in P cells also
is another effective therapeutic strategy. Indeed, the delay induced
by an increase of 15% on W4/1=k4/k1 is comparable to that
caused by unselective eradication of 99.99% of the tumor cell mass
(Figure 7B).
Concluding remarks
In summary, in this study, we presented a first version of a
conceptually simple model, with an analytical solution, that is
capable of describing the basic kinetic features of tumor growth
during the exponential phase and that is consistent with the
Cancer Stem Cell hypothesis. Three cell subpopulations were
considered: CSCs, progenitors (P), and terminally differentiated
(D) cells. Each event related to cell division or death of each one of
these subpopulations has been represented and modeled as a
chemical reaction. This resulted in an analytically solvable set of
ordinary differential equations that describes the time evolution of
each cell subpopulation, as well as the overall tumor volume
evolution during exponential growth.
Although, in principle, an infinite set of combinations of model
parameter can be studied, we found that only a limited set of
model solutions is feasible if some biologically sound constraints
are imposed. For example, if we accept that the fraction of cancer
stem cells during the exponential phase of the tumor is practically
constant and no greater than 0.01 (namely d[CNC/N]/dt=0 with
CSC/N,0.01), then only a reduced set of solutions is feasible. The
analysis of those sets suggests kinetic commonalities in solid tumor
growth: (a) the rates of symmetrical and asymmetrical CSC
renewal must be in the same order of magnitude; (b) the intrinsic
rate of renewal and differentiation of progenitor cells should be
half an order of magnitude higher than the corresponding intrinsic
rates for cancer stem cells; (c) the rates of apoptosis of the CSC, P,
and D cells are progressively higher by approximately one order of
magnitude. The flexibility of the model was tested by fitting
experimental data sets from three different tumor growth
scenarios. After adequate scaling, a single set of kinetic parameters
can be used for adequate reproduction of different tumor growth
cases.
We do not claim that our model renders accurate information
about the kinetics of solid tumor formation, but we observe that it
does provide insight into several underlying kinetic behaviors of
solid tumor growth that would be difficult to directly study
experimentally. As illustrated in this work, the model can even be
useful for anticipating the effect of different therapeutic strategies
(available or potential) against cancer.
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